Source - RNS
RNS Number : 2541J
Deltex Medical Group PLC
08 September 2016


8 September 2016



Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")



Three new US platform programme accounts



Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added three additional accounts to its platform programme in the USA.


Two of the new platform accounts are in the Company's North-East territory and the third in the Mid-West. They bring the total number of platform accounts to 27, further illustrating the success of the Company's focus on developing the USA as its key market.


·      The Company has designated one of three newly opened paediatric hospital accounts as a platform account. It is one of the largest and best regarded childrens' hospitals in the USA, thus positioned to play a key role in developing and promoting ODM applications in children. The Company's strategy in paediatric accounts is to support incremental usage by individual clinicians towards scaleable clinical protocols and is starting each account from a low base.


·      The Company has opened two new hospitals within a six hospital system planning to roll-out the successful enhanced recovery programme from the largest hospital which has been a platform account since 2014. One of the two new hospitals is considerably larger than the other and has the potential to use over 100 probes a month over time: its current plans would get it to 50 to 60 probes a month by the end of 2017 and it has therefore been designated a platform account.


·      The third account is a University level 1 trauma hospital. The procurement agreement has neither minimum nor maximum contractual quanities and the implementation model is predicated on that deployed successfully at one of the Company's earliest and largest platform accounts which uses 150 to 200 probes a month: the new account has recruited one of the clinical leads from the original account to lead the new implementation.


Ewan Phillips, Deltex Medical's Chief Executive, commented:


"Growth rates in the USA, our main focus market, continue to climb and to outstrip other territories. These three new platform accounts bring the total number to 27 and move us very close to our key short term milestone of 30 platform accounts."


For further information, please contact:-


Deltex Medical Group plc                               

01243 774 837

[email protected]

Nigel Keen, Chairman                        

Ewan Phillips, Chief Executive          

Jonathan Shaw, Group Finance Director

Barry Curtis, Company Secretary       

Nominated Adviser & Broker

Arden Partners plc

020 7614 5900

Chris Hardie


Financial Public Relations

IFC Advisory

0203 053 8671

Tim Metcalfe

Graham Herring

Heather Armstrong



Notes for Editors


Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.


Company goal


ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.


The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.


There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.


This information is provided by RNS
The company news service from the London Stock Exchange